MX2017003436A - Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. - Google Patents

Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Info

Publication number
MX2017003436A
MX2017003436A MX2017003436A MX2017003436A MX2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A
Authority
MX
Mexico
Prior art keywords
eye
drug
delivery
protection
anterior segment
Prior art date
Application number
MX2017003436A
Other languages
English (en)
Inventor
Paul G Chaney
Martin B Wax
P Bingaman David
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX2017003436A publication Critical patent/MX2017003436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente solicitud está relacionada a formulaciones tópicas que comprenden al Compuesto-I (ver Fórmula) o su base libre, y un segundo agente activo seleccionado de ácido nicotínico, nicotinamida, y vitamina K, y una combinación de los mismos, para el tratamiento de neovascularización ocular; la presente solicitud también está relacionada a composiciones farmacéuticas que comprenden partículas del Compuesto-I o su base libre, y formulaciones de suspensión que comprenden las composiciones de partícula del Compuesto-I o su base libre.
MX2017003436A 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. MX2017003436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Publications (1)

Publication Number Publication Date
MX2017003436A true MX2017003436A (es) 2017-07-28

Family

ID=55453708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003436A MX2017003436A (es) 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Country Status (19)

Country Link
US (5) US9814702B2 (es)
EP (2) EP3193867B1 (es)
JP (3) JP6657193B2 (es)
KR (2) KR102450020B1 (es)
CN (2) CN106999476B (es)
AU (2) AU2015317531B2 (es)
CA (1) CA2958315A1 (es)
DK (1) DK3193867T3 (es)
ES (1) ES2863601T3 (es)
HU (1) HUE053852T2 (es)
IL (2) IL282504B (es)
MA (1) MA56220A (es)
MX (2) MX2017003436A (es)
NZ (1) NZ767710A (es)
PL (1) PL3193867T3 (es)
PT (1) PT3193867T (es)
RU (2) RU2704810C2 (es)
WO (1) WO2016044671A1 (es)
ZA (1) ZA201701303B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3193867B1 (en) * 2014-09-17 2021-01-20 PanOptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
JP7039606B2 (ja) * 2018-07-18 2022-03-22 温州医科大学 近視の治療方法及び薬物調製における応用
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2792997A (en) * 1997-05-26 1998-12-30 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
KR20030059275A (ko) * 2000-11-28 2003-07-07 화이자 프로덕츠 인크. 이소티아졸-4-카복사미드의 염 및 과증식-억제제로서의그의 용도
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
JP2008520576A (ja) * 2004-11-16 2008-06-19 ニュー‐ティーン カンパニー，インク． 眼性血管新生症および黄斑変性の処置に有用な組成物
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
IN2012DN01846A (es) * 2009-08-11 2015-08-21 Allergan Inc
KR20120100964A (ko) * 2009-09-30 2012-09-12 바이타패스 제네틱스 인코포레이티드 개인용 보조인자 및 사용 방법
JP2013531067A (ja) * 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
CN103209683B (zh) * 2010-08-17 2016-08-31 Ohr制药股份有限公司 角鲨胺的眼用制剂
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
ES2791751T3 (es) * 2011-11-15 2020-11-05 Allergan Inc Suspensiones de forma 2 de ciclosporina A
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US10092549B2 (en) 2013-03-14 2018-10-09 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
EP3193867B1 (en) * 2014-09-17 2021-01-20 PanOptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Also Published As

Publication number Publication date
CA2958315A1 (en) 2016-03-24
CN106999476B (zh) 2021-05-04
AU2021200997A1 (en) 2021-03-11
HUE053852T2 (hu) 2021-07-28
DK3193867T3 (da) 2021-04-06
NZ767710A (en) 2023-09-29
JP6657193B2 (ja) 2020-03-04
JP7176042B2 (ja) 2022-11-21
EP3193867A4 (en) 2018-05-02
ES2863601T3 (es) 2021-10-11
IL251019B (en) 2021-05-31
CN113209000A (zh) 2021-08-06
RU2704810C2 (ru) 2019-10-31
JP6890692B2 (ja) 2021-06-18
IL282504A (en) 2021-06-30
KR20220137157A (ko) 2022-10-11
RU2017112930A (ru) 2018-10-17
PT3193867T (pt) 2021-03-09
JP2020079274A (ja) 2020-05-28
EP3878449A1 (en) 2021-09-15
NZ729142A (en) 2023-08-25
BR112017005523A2 (pt) 2017-12-05
RU2017112930A3 (es) 2019-04-11
EP3193867B1 (en) 2021-01-20
US9814702B2 (en) 2017-11-14
US20180078531A1 (en) 2018-03-22
EP3193867A1 (en) 2017-07-26
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
US20210275501A1 (en) 2021-09-09
KR102555091B1 (ko) 2023-07-13
US9623011B2 (en) 2017-04-18
ZA201701303B (en) 2021-07-28
US10183014B2 (en) 2019-01-22
US20160206599A1 (en) 2016-07-21
MX2021006070A (es) 2021-07-06
US20160074371A1 (en) 2016-03-17
WO2016044671A1 (en) 2016-03-24
PL3193867T3 (pl) 2021-07-12
JP2021121624A (ja) 2021-08-26
IL282504B (en) 2022-08-01
KR20170058976A (ko) 2017-05-29
JP2017527600A (ja) 2017-09-21
MA56220A (fr) 2022-04-20
RU2768652C1 (ru) 2022-03-24
US20190314343A1 (en) 2019-10-17
KR102450020B1 (ko) 2022-09-30
IL251019A0 (en) 2017-04-30
AU2015317531B2 (en) 2020-11-19
CN106999476A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2015013396A (es) Derivados de quinolinas como nuevos agentes contra el cancer.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2016012994A (es) Derivados de piridina macrociclicos.
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2016007440A (es) Inhibidores del bromodominio.
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
PH12019500024A1 (en) Pharmaceutical compositions
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.